Pune, India, May 21, 2019 (GLOBE NEWSWIRE) -- According to a report published by Market Research Future (MRFR), the global prils market has been assessed to reach a valuation of USD 2,591.5 million until 2023 and is estimated to grow at a compound annual growth rate of 4.3% over the forecast period from 2019 to 2023.
A pril is a small molecule or an active pharmaceutical ingredient (API), which is an essential biological component used in drugs for its therapeutic properties.
Different types of prils have different functions, which are used to cure various disorders. Ramipril is an angiotensin-converting enzyme (ACE) inhibitor and has the ability to normalizes the blood vessels and blood flow, lower the risk of stroke, heart attack, and reduces kidney-related complications and is commonly used for treating hypertension. Similarly, other APIs like benazepril, cilazapril, and quinapril possess various healing properties and are used in the treatment procedure for various chronic diseases.
Request Free Sample @ https://www.marketresearchfuture.com/sample_request/7692
The global prils market has been assessed to grow exponentially over the forecast period, due to the growing prevalence of diseases, caused by the sedentary lifestyle of consumers, and the rise in geriatric population, which are contributing to the demand in the global prils market.
Additionally, the market is expected to grow owing to influential factors such as the rapid growth of the API industry and pharmaceutical industry, the increasing expenditure on research and development by pharmaceutical, biotech companies, and other healthcare establishments towards development and enhancement of effective drug therapies.
Key Players
The key players in the global prils market are –
- Lupin
- Pfizer Inc.
- Mylan N.V.
- F. Hoffmann-La Roche
- Aurobindo Pharma
- Sun Pharmaceutical Industries Ltd
- Merck KGaA
- Manus Aktteva Biopharma LLP
- Canagen Pharmaceuticals Inc.
- Novartis AG
Segmental Analysis
The global prils market has been segmented on the basis of type, application, and region.
Based on type, the market has been segmented into ramipril, quinapril, cilazapril, and benazepril. Ramipril has been estimated to lead the market share, since it is commonly prescribed to heart patients, and the growing prevalence of heart diseases is a driving factor for the ramipril segment. It has been assessed to record a valuation of
Based on application, the Prils Market has been segmented into hypertension, heart failure, chronic kidney disorder, and others. Hypertension segment expected to lead the market share in the application segment due to the increase in the prevalence of cardiovascular diseases and the rise in the geriatric population raises the risks for the heart-related disorder. The growing use of tobacco and smoking also raises the risk of cardiovascular problems.
A modern sedentary lifestyle has led to the alarming prevalence of multiple chronic diseases, such as obesity, risk of cardiovascular diseases, high blood pressure, anxiety, depression, which consequently lead to more diseases. The heart failure segment has been assessed to record the second largest market share.
Based on the region, the market has been segmented into North America and South America, Europe, Asia Pacific, and the Middle East and Africa.
Browse the market data and information spread across 153 pages with 80 data tables and 16 figures of the report “Prils Market - Forecast 2019-2023” in-depth alongside table of content (TOC) at: https://www.marketresearchfuture.com/reports/prils-market-7692
North America Leading the Global Prils Market Share, Followed By Europe; APAC Estimated To Be Lucrative
The Americas are the leading region in the global prils market, primarily owing to the technological advancements in the healthcare industry and the rise in the patient population. Additionally, there is a vast scope of opportunities over the forecast period, for the development and growth of the prils market in North America, due to the well-established pharmaceutical industry in the U.S. and Canada.
Europe is the second largest region in the global prils market and is estimated to record a high market share. Favorable government policies and initiatives towards supporting generic drug growth with pricing and reimbursement are influential factors for market growth over the forecast period.
Asia Pacific region has been assessed as an emerging market for prils, owing to the increasing investment in the healthcare sector by the governments, increasing number of trained medical professionals, and the rising demand for effective drug therapies due to the rising prevalence of life-threatening disorders and chronic diseases, in populated countries like China and India. Asia Pacific is estimated to be a lucrative prils market over the forecast period.
Make an Enquiry Before Buying this Report @ https://www.marketresearchfuture.com/enquiry/7692
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.